Literature DB >> 20844427

HIV-1 infection and antiretroviral therapies: risk factors for osteoporosis and bone fracture.

Ighovwerha Ofotokun1, M Neale Weitzmann.   

Abstract

PURPOSE OF REVIEW: Patients with HIV-1 infection/AIDS are living longer due to the success of highly active antiretroviral therapy (HAART). However, serious metabolic complications including bone loss and fractures are becoming common. Understanding the root causes of bone loss and its potential implications for aging AIDS patients will be critical to the design of effective interventions to stem a tidal wave of fractures in a population chronically exposed to HAART. RECENT
FINDINGS: Paradoxically, bone loss may occur not only due to HIV/AIDS but also as a consequence of HAART. The cause and mechanisms driving these distinct forms of bone loss, however, are complex and controversial. This review examines our current understanding of the underlying causes of HIV-1 and HAART-associated bone loss, and recent findings pertaining to the relevance of the immuno-skeletal interface in this process.
SUMMARY: It is projected that by 2015 more than half of the HIV/AIDS population in the USA will be over the age of 50 and the synergy between HIV and/or HAART-related bone loss with age-associated bone loss could lead to a significant health threat. Aggressive antiresorptive therapy may be warranted in high-risk patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20844427      PMCID: PMC3632052          DOI: 10.1097/MED.0b013e32833f48d6

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  56 in total

1.  Alterations in the immuno-skeletal interface drive bone destruction in HIV-1 transgenic rats.

Authors:  Tatyana Vikulina; Xian Fan; Masayoshi Yamaguchi; Susanne Roser-Page; Majd Zayzafoon; David M Guidot; Ighovwerha Ofotokun; M Neale Weitzmann
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-19       Impact factor: 11.205

2.  Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.

Authors:  Y Y Kong; U Feige; I Sarosi; B Bolon; A Tafuri; S Morony; C Capparelli; J Li; R Elliott; S McCabe; T Wong; G Campagnuolo; E Moran; E R Bogoch; G Van; L T Nguyen; P S Ohashi; D L Lacey; E Fish; W J Boyle; J M Penninger
Journal:  Nature       Date:  1999-11-18       Impact factor: 49.962

3.  Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy.

Authors:  Patrick W Mallon; John Miller; David A Cooper; Andrew Carr
Journal:  AIDS       Date:  2003-05-02       Impact factor: 4.177

4.  An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction.

Authors:  W Reid; M Sadowska; F Denaro; S Rao; J Foulke; N Hayes; O Jones; D Doodnauth; H Davis; A Sill; P O'Driscoll; D Huso; T Fouts; G Lewis; M Hill; R Kamin-Lewis; C Wei; P Ray; R C Gallo; M Reitz; J Bryant
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-31       Impact factor: 11.205

5.  T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma.

Authors:  H Takayanagi; K Ogasawara; S Hida; T Chiba; S Murata; K Sato; A Takaoka; T Yokochi; H Oda; K Tanaka; K Nakamura; T Taniguchi
Journal:  Nature       Date:  2000-11-30       Impact factor: 49.962

Review 6.  Bone resorption by osteoclasts.

Authors:  S L Teitelbaum
Journal:  Science       Date:  2000-09-01       Impact factor: 47.728

7.  The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling.

Authors:  Michael W-H Wang; Shi Wei; Roberta Faccio; Sunao Takeshita; Pablo Tebas; William G Powderly; Steven L Teitelbaum; F Patrick Ross
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

8.  Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.

Authors:  Joel E Gallant; Schlomo Staszewski; Anton L Pozniak; Edwin DeJesus; Jamal M A H Suleiman; Michael D Miller; Dion F Coakley; Biao Lu; John J Toole; Andrew K Cheng
Journal:  JAMA       Date:  2004-07-14       Impact factor: 56.272

Review 9.  AIDS and older Americans at the end of the Twentieth Century.

Authors:  Karin A Mack; Marcia G Ory
Journal:  J Acquir Immune Defic Syndr       Date:  2003-06-01       Impact factor: 3.731

10.  Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals.

Authors:  Kristin Mondy; Kevin Yarasheski; William G Powderly; Michael Whyte; Sherry Claxton; Debra DeMarco; Mary Hoffmann; Pablo Tebas
Journal:  Clin Infect Dis       Date:  2003-01-29       Impact factor: 9.079

View more
  30 in total

1.  Bone disease in HIV infection.

Authors:  Maristella Francesca Saccomanno; Adriana Ammassari
Journal:  Clin Cases Miner Bone Metab       Date:  2011-01

2.  Zinc-finger nuclease editing of human cxcr4 promotes HIV-1 CD4(+) T cell resistance and enrichment.

Authors:  Jinyun Yuan; Jianbin Wang; Karen Crain; Colleen Fearns; Kenneth A Kim; Kevin L Hua; Philip D Gregory; Michael C Holmes; Bruce E Torbett
Journal:  Mol Ther       Date:  2012-01-24       Impact factor: 11.454

3.  CTLA-4Ig-induced T cell anergy promotes Wnt-10b production and bone formation in a mouse model.

Authors:  Susanne Roser-Page; Tatyana Vikulina; Majd Zayzafoon; M Neale Weitzmann
Journal:  Arthritis Rheumatol       Date:  2014-04       Impact factor: 10.995

4.  Hemin activation of innate cellular response blocks human immunodeficiency virus type-1-induced osteoclastogenesis.

Authors:  Kazuyo Takeda; Rewati Adhikari; Kenneth M Yamada; Subhash Dhawan
Journal:  Biochem Biophys Res Commun       Date:  2015-05-19       Impact factor: 3.575

5.  Serum total estradiol, but not testosterone is associated with reduced bone mineral density (BMD) in HIV-infected men: a cross-sectional, observational study.

Authors:  D Santi; B Madeo; F Carli; S Zona; G Brigante; F Vescini; G Guaraldi; V Rochira
Journal:  Osteoporos Int       Date:  2015-10-28       Impact factor: 4.507

Review 6.  HIV and bone metabolism.

Authors:  Ighovwerha Ofotokun; M Neale Weitzmann
Journal:  Discov Med       Date:  2011-05       Impact factor: 2.970

7.  Association of Blood Biomarkers of Bone Turnover in HIV-1 Infected Individuals Receiving Anti-Retroviral Therapy (ART).

Authors:  Najib Aziz; Anthony W Butch; Joshua J Quint; Roger Detels
Journal:  J AIDS Clin Res       Date:  2014

8.  Do γδ T cells predict osteonecrosis of the jaw?

Authors:  M Neale Weitzmann
Journal:  J Bone Miner Res       Date:  2013-04       Impact factor: 6.741

Review 9.  HIV infection and osteoporosis: pathophysiology, diagnosis, and treatment options.

Authors:  Micol S Rothman; Mary T Bessesen
Journal:  Curr Osteoporos Rep       Date:  2012-12       Impact factor: 5.096

10.  Antiretroviral therapy induces a rapid increase in bone resorption that is positively associated with the magnitude of immune reconstitution in HIV infection.

Authors:  Ighovwerha Ofotokun; Kehmia Titanji; Aswani Vunnava; Susanne Roser-Page; Tatyana Vikulina; Francois Villinger; Kenneth Rogers; Anandi N Sheth; Cecile Delille Lahiri; Jeffrey L Lennox; M Neale Weitzmann
Journal:  AIDS       Date:  2016-01-28       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.